Back

Antiphospholipid antibodies are associated with subclinical cardiac impairment in patients with SLE

31 August 2025 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Inflammation in focus Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Oscar Azael Garza Flores

Monterrey (Mexico)

5 More presentations in this session

Presentation thumbnail
CCL17 as a biomarker of premature atherosclerosis in the early development of systemic lupus erythematosus: insights from the Chinese CSTAR cohorts
Sir J. Wu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Association between systemic lupus erythematosus and myocardial infarction subtypes - a matched cohort study in Sweden
Doctor I. Samuelsson (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Similar myocardial infarction characteristics and short-term outcomes in patients with and without inflammatory joint diseases: results from a Nationwide Norwegian study
Doctor E. Ikdahl (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Carotid intima-media thickness in middle-aged adults with and without rheumatoid arthritis: a case-cohort analysis
Mrs P. Estrada (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Coronary artery calcium in middle-aged adults with and without rheumatoid arthritis: a case-cohort analysis.
Mrs P. Estrada (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Inflammation in focus

The Event

Event poster

ESC Congress 2025

31 August 2025 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of adverse cardiac events in a large cohort of patients with antiphospholipid syndrome
thumbnail
Congress Presentation
Cardiac abnormalities and the presence of modifiable cardiovascular risk factors in patients with systemic lupus erythematosus
thumbnail
Congress Presentation
Cardiovascular risk in rare autoimmune diseases, lessons from a primary antiphospholipid syndrome patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources